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ric cancers. Methods: Current oncology PIPs were manually extracted from the 
EMA website for the study period 2007-2014. Primary variables included: indication, 
applicant, decision, decision date, and date of expected completion. Indications for 
approved PIPs were classified into five categories: brain tumors, diagnostics, leuke-
mias/lymphomas, side effects, and solid tumors. Results: A total of 105 PIPs were 
found; 36 of which were waivers, and 69 of which were approved. The study found 
that 39% (27) of approved PIPs were indicated for solid tumors, including melanomas 
and malignant tumors; 30% (21) of approved PIPs were indicated for leukemias or 
lymphomas; 17% (12) of approved PIPs were indicated for chemotherapy-induced 
side effects, such as anti-nausea and neuotropenia medications; 12% (8) of approved 
PIPs were indicated for brain tumors; and one oncology diagnostic PIP was also 
approved. The ramp-up of the PIP program was significant. PIPs approved in 2013 
and the first half of 2014 accounted for 54% (37) of all PIPs approved during the study 
period. ConClusions: Approved PIPs covered a wide range of pediatric cancers, 
and the number of approved PIPs increased significantly over time. While the ramp-
up of the PIP program indicated that it was successful in promoting research in 
this area, serious concerns remained regarding the feasibility of the program. For 
example, there were currently four trials planned for completion between 2015-
2020 for extremely rare high grade gliomas. This limitation may compromise the 
integrity of the PIP program.
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objeCtives: Little information is available on the patterns of chemotherapy regi-
mens administered for the treatment of ovarian cancer (OC) in the Netherlands. 
The objective for this study was to describe current chemotherapy patterns for OC 
in the Netherlands and to evaluate survival outcomes following subsequent lines 
of chemotherapy. Methods: Data from the Eindhoven Cancer Registry, including 
data on all newly diagnosed cancer patients, was linked to the PHARMO Database 
Network including, among other things, information on in- and outpatient drug use. 
Patients diagnosed with primary OC between January 2000 and December 2010 were 
selected. First and subsequent chemotherapy regimens were defined as the start of 
a different (combination of) chemotherapeutic agent (s) or a gap > 42 days (or > 91 
or > 183 days in sensitivity analysis) between two treatment cycles. Results: Of 
the included OC patients, 70% received chemotherapy as initial treatment. Detailed 
chemotherapy data were available for 261 patients, who had a mean age of 63 (SD 
12) years. Pathological tumor stage was known for 77% of patients, of whom 11%, 
55% and 17% of patients had disease stage II, III, and IV, respectively. In first line 
chemotherapy, 76% of patients received platinum/taxane doublet chemotherapy. 
Of the 161 patients receiving second line chemotherapy, platinum-containing 
chemotherapy was received by 63% of patients (101 of whom 13 received platinum 
monotherapy). In third line chemotherapy this was 51% (53 patients). At least eight 
lines of chemotherapy were identified in 12 cases. Median survival as from diag-
nosis was 46 months. After second line chemotherapy, median survival remained 
14 months. ConClusions: This study provides detailed information on the type 
of chemotherapy regimens administered to OC patients at initial diagnosis and 
during follow-up and the survival following the various chemotherapy regimens.
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objeCtives: Erythropoietin stimulating agents (ESAs) are useful drugs for treating 
chemotherapy related anemia to reduce the number of blood transfusions. However, 
there were unrecognized toxicities of ESAs. These toxicities were finally recognized 
in 2007 when the FDA issued a black box warning for ESAs. The objective of this 
study is to determine the effect of the FDA black box warning on ESA use pat-
terns and associated outcomes in insured, low-income cancer patients in South 
Carolina. Methods: The merged South Carolina Central Cancer Registry-Medicaid 
dataset was used to determine the trend of ESA use from 2001-2010. Female Breast, 
Colorectal and Non-Small Cell Lung cancer patients were identified from the reg-
istry. Of those, their chemotherapy status was identified along with ESA use from 
Medicaid medical claims. The major outcome measures were claims for use of ESAs 
after chemotherapy and the blood transfusion rate. Logistic regression was used as 
a quantitative method to determine if the likelihood of receiving ESA treatment was 
reduced after FDA black box warning. Results: Among 1,645 patients treated with 
chemotherapy from 2002-2010, the proportion of chemotherapy patients receiving 
ESAs decreased from 56.47 % before the black box warning to 23.16% after black box 
warning (p < 0.001). The blood transfusion rate per year during 2002-2007 remained 
around 10-15% and increased to 31% in 2009. The likelihood of ESA use was reduced 
by 63% after black box warning issued by FDA after adjusting for demographic and 
clinical variables. ConClusions: The black box warning may have been effective 
in reducing overall ESA utilization in cancer patients taking chemotherapy.
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to reimbursements, causing a significant growth in costs. Expenses for oncology in 
2003-2011 increased by 718% (from € 15.4 million to € 125.7 million). In December 
2011, a cost/QALY threshold was introduced to legislation, creating a barrier to 
the inclusion of oncology drugs to the Reimbursement list. Following adoption of 
this legislation, of the 12 drugs registered by the EMA, only 3 oncology drugs were 
included to the List during 2012-2014. Uncategorized drugs are available only for a 
limited number of patients by way of individual exceptions, or by participation in 
clinical trials. ConClusions: In Slovakia, the willingness to pay for an additional 
unit of health was anchored in legislation, which greatly limited the availability of 
innovative oncological treatment. The health system in Slovakia needs to intro-
duce efficient and transparent mechanisms that enable the treatment of oncology 
patients in line with the latest medical findings, while keeping expenses for treat-
ment within economic possibilities.
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objeCtives: Across geographies, approval, pricing and reimbursement of phar-
maceuticals take place under varying timelines with different outcomes. There 
are some countries that may obtain access to new pharmaceuticals through early 
access schemes. Breakthrough and innovative products that are thought to have a 
profound impact on current standard of care are often eligible for quicker routes to 
access. This research sought to investigate how these schemes worked, where they 
were prevalent, and the outcomes of such schemes. Methods: The research was 
conducted through in-depth interviews with payers and clinicians across 10 EMEA 
markets. Results: Of the 10 markets studied, 5 countries were identified to have 
either easier or quicker routes to access for new biopharmaceuticals (e.g., ATU in 
France and Algeria, law 648/96 in Italy, non-formulary access in Saudi Arabia, and 
the “white list” in Norway). Most often, these routes were reserved for products with 
orphan indications or products that were believed to significantly impact current 
standard of care. If pharmaceutical companies opt for the streamlined route, there 
are often significant restrictions imposed on the product, as well as a reduction 
in volume. If companies elect for the standard route to approval and reimburse-
ment, the review process is often more rigorous, however, the decision is likely 
more permanent and the volume of product is larger. Frequently, if products opt 
for the faster route to access, this will serve as additional evidence for getting the 
product reimbursed at a later date for use in a wider population. ConClusions: 
New pharmaceutical products that are likely to dramatically change the treatment 
landscape or are active in orphan diseases should take advantage of these schemes. 
Physicians grasp at the opportunity to use efficacious products as early as possible 
and companies need to leverage the opportunity for streamlined access to products.
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objeCtives: Lung cancer has a continuously bad prognosis in terms of survival 
and quality of life, usually because of late detection of malignancies. Given an 
expected increase in the incidence, overall mortality will increase. Early detec-
tion and efficient diagnostic planning may offer additional gain in survival. The 
diagnostic pathway for patients with suspected lung cancer is characterized by a 
cascade of different imaging and diagnostic modalities. The main objective of this 
study is to estimate the health economic impact of diagnostic procedures and the 
expected gain by volume-doubling time on low-dose CT as biomarker in suspected 
lung cancer (NELSON protocol). Methods: A state-transition model is created to 
simulate the pathway of lung cancer diagnostic procedures, including x-ray, diag-
nostic CT, PET-CT, bronchoscopy, mediastinoscopy and more. Hospital registries 
and data from the National Cancer Registry were used to estimate the amount of 
diagnostic procedures in a cohort of lung cancer patients. Systematic literature 
search was performed to estimate the diagnostic performance of different modali-
ties. Patient cohort is defined and the pre-test probability for malignancy is esti-
mated through the Swensen criteria. Probabilistic sensitivity analysis is performed 
using Monte Carlo Simulations. Results: Diagnostic procedures for patients with 
suspected lung cancer can count up to almost € 3000 per patient. Pathway was 
modeled in a microsimulated cohort through Swensen criteria, leading to a mean 
chance of malignancy of 40%. Costly steps in the pathway include cervical medi-
astinoscopy and mutation analysis. Inclusion of NELSON protocol can lead to a 
reduction in costs. Decision making per patient can reduce overuse of diagnostic 
modalities. ConClusions: The diagnostic procedure for suspected lung cancer 
patients is a costly pathway and can be improved with use of the NELSON screening 
protocol or personalized selection of diagnostic procedures.
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objeCtives: The European Pediatric Medicine Regulation was created in 2007 to 
encourage further drug development for pediatric diseases, by requiring pharma-
ceutical companies to submit pediatric investigation plans (PIPs) when submitting 
the marketing application for a new drug. The objective of this study was to deter-
mine how successful this legislation had been in stimulating research in pediat-
